课题基金 / 基金详情

ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD)

ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD)
控制糖尿病心血管风险的行动(协议)
批准号:
7376662
负责人:
JOHN R CROUSE
金额:
$49.06万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-17 至 2007-02-28

项目摘要

项目成果

JOHN R CROUSE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ACCORD Trial is designed to evaluate the effect of different ways to control blood sugar, blood pressure, and blood lipids (fats in the blood) to reduce the risk of heart disease and stroke in adults with Type 2 (adult-onset) diabetes. A total of 10,000 participants will be enrolled from approximately 60 sites across the USA and Canada. The primary outcome is the first occurrence of a major cardiovascular disease event.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AIM-HIGH CAROTID MRI STUDY
CLINICAL TRIAL: AIM-HIGH: ATHEROSCLEROSIS INTERVENTIONIN MATABOLIC SYNDROME WIT
CLINICAL TRIAL: ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD)
CLINICAL TRIAL: ACTION TO CONTROL CARDIOVASCULAR RISKS IN DIABETES (ACCORD)
国内基金
海外基金
基于MFSD2A调控血迷路屏障跨细胞囊泡转运机制的噪声性听力损失防治研究
  • 批准号:
    82371144
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    汪雪玲
  • 依托单位:
内源性蛋白酶抑制剂SerpinA3N对缺血性脑卒中后血脑屏障的保护作用及其表达调控机制
  • 批准号:
    82371317
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    万杰清
  • 依托单位:
KLK10调控胶质—血管耦合与对话促缺血性卒中后血脑屏障修复的机制
  • 批准号:
    82371465
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    李龙宣
  • 依托单位:
骨骼肌中胰高血糖素受体的表达及其调控血糖稳态的作用与机制研究
  • 批准号:
    82370820
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    王天歌
  • 依托单位: